Skip to content

Lineage Cell Therapeutics, Inc.: 10-Q filed 2011-08-09

What Lineage Cell Therapeutics, Inc. reported in its quarterly report filed 2011-08-09 (fiscal Q2 2011): 32 published measures, 80 facts as tagged in accession 0001140361-11-040659.

This filing

Form
10-Q (quarterly report)
Filed
2011-08-09
Fiscal period
fiscal Q2 2011
Accession
0001140361-11-040659 on SEC EDGAR

Values are as tagged in this filing. A later filing can restate them; each measure links to its history page, which shows the latest-filed value per period. All Lineage Cell Therapeutics, Inc. filings.

Reported measures

Total assets

Resources recognized on the balance sheet. Book assets are not the market value of the business.

PeriodValueUnitDays
At 2011-06-3053,457,744USD
At 2010-12-3153,272,659USD

Stockholders equity

The reported residual interest after liabilities. It is an accounting amount, not market capitalization.

PeriodValueUnitDays
At 2011-06-3036,143,817USD
At 2010-12-3138,172,229USD

Cash and cash equivalents

Cash and qualifying short-term liquid investments under the filer’s accounting policy. Restricted cash and longer-term investments may be reported separately.

PeriodValueUnitDays
At 2011-06-3027,381,941USD
At 2010-12-3133,324,924USD
At 2010-06-3018,056,089USD
At 2009-12-3112,407,350USD

Net income or loss

Reported profit or loss for the period. Check the filing for attribution, exceptional items and discontinued operations before comparing companies.

PeriodValueUnitDays
2011-04-01 to 2011-06-30-4,277,928USD91
2011-01-01 to 2011-06-30-7,642,222USD181
2010-04-01 to 2010-06-30-2,259,775USD91
2010-01-01 to 2010-06-30-3,546,538USD181

Operating cash flow

Cash generated or used by operating activities. Working-capital timing can make this differ substantially from reported income.

PeriodValueUnitDays
2011-01-01 to 2011-06-30-6,402,906USD181
2010-01-01 to 2010-06-30-2,962,791USD181

Capital expenditure payments

Cash payments to acquire property, plant and equipment. This taxonomy concept does not capture every form of investment or acquisition.

PeriodValueUnitDays
2011-01-01 to 2011-06-30537,959USD181
2010-01-01 to 2010-06-30144,780USD181

Financing cash flow

Net cash from financing activities, including borrowing, repayments and transactions with owners. A positive amount does not establish operating profitability.

PeriodValueUnitDays
2011-01-01 to 2011-06-30827,381USD181
2010-01-01 to 2010-06-309,041,403USD181

Investing cash flow

Net cash from investing activities, including asset purchases, disposals and investment transactions. This differs from capital expenditure payments alone.

PeriodValueUnitDays
2011-01-01 to 2011-06-30-530,153USD181
2010-01-01 to 2010-06-30-435,783USD181

Retained earnings or deficit

Accumulated undistributed earnings or deficit at the reporting date. This balance is not cash available for distribution.

PeriodValueUnitDays
At 2011-06-30-71,596,731USD
At 2010-12-31-63,954,509USD

Net property, plant and equipment

Carrying amount of property, plant and equipment after accumulated depreciation, depletion and amortization. It is not replacement cost or market value.

PeriodValueUnitDays
At 2011-06-301,217,646USD
At 2010-12-31710,766USD

Share-based compensation expense

Reported noncash expense for share-based payment arrangements. Noncash treatment does not mean the awards have no economic cost to shareholders.

PeriodValueUnitDays
2011-01-01 to 2011-06-30560,082USD181
2010-01-01 to 2010-06-30284,130USD181

Operating income or loss

Operating revenue less operating expenses for the reporting period. It excludes items outside the reported operating result and is not free cash flow.

PeriodValueUnitDays
2011-04-01 to 2011-06-30-4,980,994USD91
2011-01-01 to 2011-06-30-9,006,459USD181
2010-04-01 to 2010-06-30-2,315,424USD91
2010-01-01 to 2010-06-30-3,641,545USD181

Current assets

Assets classified as current under the normal operating cycle or one-year boundary. Not all current assets can be converted immediately into cash.

PeriodValueUnitDays
At 2011-06-3029,419,983USD
At 2010-12-3135,572,678USD

Current liabilities

Obligations classified as current under the operating-cycle or one-year boundary. The balance includes more than short-term borrowing.

PeriodValueUnitDays
At 2011-06-303,286,882USD
At 2010-12-312,479,957USD

Operating expenses

Recurring operating costs under this accounting concept, generally excluding production costs included in cost of sales. Check filing presentation before combining expense subtotals.

PeriodValueUnitDays
2011-04-01 to 2011-06-305,736,547USD91
2011-01-01 to 2011-06-3010,587,866USD181
2010-04-01 to 2010-06-302,995,702USD91
2010-01-01 to 2010-06-305,088,951USD181

Net inventory

Inventory carrying amount after applicable valuation and LIFO reserves. It does not establish realizable selling proceeds or inventory turnover without other inputs.

PeriodValueUnitDays
At 2011-06-3056,843USD
At 2010-12-3145,470USD

Research and development expense

Research and development costs recognized as expense. Capitalization policies and acquired projects can make this differ from total cash invested in development.

PeriodValueUnitDays
2011-04-01 to 2011-06-30-3,285,286USD91
2011-01-01 to 2011-06-30-6,143,222USD181
2010-04-01 to 2010-06-30-1,429,027USD91
2010-01-01 to 2010-06-30-2,588,978USD181

Common shares outstanding

Common shares outstanding at the reporting date. This point-in-time count differs from the weighted-average shares used for earnings per share and can exclude other share classes.

PeriodValueUnitDays
At 2011-06-3048,869,323shares
At 2010-12-3147,777,701shares

Additional paid-in capital

Capital contributed above par value under this concept. It records historical contributions, not the current value of the equity or cash on hand.

PeriodValueUnitDays
At 2011-06-3093,972USD
At 2010-12-3193,972USD

Accumulated other comprehensive income or loss

Cumulative other comprehensive items after tax, such as translation and unrealized hedging or securities effects. These amounts have not passed through net income.

PeriodValueUnitDays
At 2011-06-30-701,204USD
At 2010-12-31897,338USD

Total equity including noncontrolling interests

Equity including the portion attributable to noncontrolling interests. It is larger than or equal to parent stockholders equity and is not market capitalization.

PeriodValueUnitDays
At 2011-06-3048,869,479USD
At 2010-12-3149,425,657USD

Net intangible assets excluding goodwill

Intangible assets other than goodwill after amortization and impairment. Internally developed intangibles are usually not recognized, so this understates what a company relies on.

PeriodValueUnitDays
At 2011-06-3021,645,188USD
At 2010-12-3115,386,905USD

Other noncurrent liabilities

Noncurrent liabilities the filer does not present separately. The composition differs by filer and is described only in the filing.

PeriodValueUnitDays
At 2011-06-30297,590USD
At 2010-12-31318,288USD

Prepaid expenses and other current assets

Prepayments and other current assets grouped under this concept. The balance is not cash and its composition differs by filer.

PeriodValueUnitDays
At 2011-06-301,981,199USD
At 2010-12-312,202,284USD

Profit or loss including noncontrolling interests

Net income or loss including the portion attributable to noncontrolling interests. It can differ from the net income attributable to the parent that per-share figures use.

PeriodValueUnitDays
2011-04-01 to 2011-06-30-5,000,316USD91
2011-01-01 to 2011-06-30-8,944,601USD181
2010-04-01 to 2010-06-30-2,353,786USD91
2010-01-01 to 2010-06-30-3,665,810USD181

General and administrative expense

General and administrative costs reported under this concept, separate from selling expense. Filers group overhead differently, so compare presentation before comparing companies.

PeriodValueUnitDays
2011-04-01 to 2011-06-30-2,451,261USD91
2011-01-01 to 2011-06-30-4,444,644USD181
2010-04-01 to 2010-06-30-1,566,675USD91
2010-01-01 to 2010-06-30-2,499,973USD181

Depreciation expense

Depreciation recognized for the period under this concept. It is a noncash allocation of asset cost and may exclude amortization and depletion reported elsewhere.

PeriodValueUnitDays
2011-01-01 to 2011-06-30128,215USD181
2010-01-01 to 2010-06-3031,221USD181

Amortization of intangible assets

Amortization recognized on finite-lived intangible assets. It follows acquisition accounting and does not indicate the intangibles are losing usefulness at that rate.

PeriodValueUnitDays
2011-01-01 to 2011-06-301,041,520USD181
2010-01-01 to 2010-06-30128,333USD181

Nonoperating income or expense

Total nonoperating income or expense, which can include interest, investment results and other items. A positive value is not operating profit.

PeriodValueUnitDays
2011-04-01 to 2011-06-30-19,322USD91
2011-01-01 to 2011-06-3061,858USD181
2010-04-01 to 2010-06-30-38,362USD91
2010-01-01 to 2010-06-30-24,265USD181

Proceeds from issuing common stock

Cash received from issuing common stock during the period. It is gross of costs only where the filer reports it so, and it does not include noncash issuances.

PeriodValueUnitDays
2011-01-01 to 2011-06-30213,500USD181
2010-01-01 to 2010-06-300USD181

Change in accounts receivable

The cash flow adjustment for the change in receivables during the period. A positive value under this concept means receivables grew and reduced operating cash flow.

PeriodValueUnitDays
2011-01-01 to 2011-06-30-121,922USD181
2010-01-01 to 2010-06-3032,607USD181

Change in inventories

The cash flow adjustment for the change in inventories during the period. A positive value under this concept means inventory grew and reduced operating cash flow.

PeriodValueUnitDays
2011-01-01 to 2011-06-3025,425USD181
2010-01-01 to 2010-06-30-11,094USD181

Inspect the source

Entity
Lineage Cell Therapeutics, Inc. / CIK 0000876343
Captured
2026-09-20T05:01:04.503Z
SEC response SHA-256
de850ac42665e48058d541d948514740e0c9007b61646401dcae831c504c80bf

Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON

Every published concept a filing tagged, with the periods it covered, as reported in that filing at capture time. Forms 10-K, 10-K/A, 10-Q, 10-Q/A, 20-F, 20-F/A, 40-F, 40-F/A. A filing page needs at least 8 published concepts. Later filings can restate these values; the company history pages show the latest-filed value per period.

Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.

Use this in research

A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.

These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.

Research methodology · Execution and cost assumptions · Check backtest overfitting

Build with the open-source tools

Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.

Read the published dataset with Python
import json
from urllib.request import urlopen

with urlopen("https://canlicapital.com/company-data/0000876343.json") as response:
    record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
    print(concept["tag"], next(iter(concept["observations"])))